Pharmaceuticals
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts Increasing Discovery Efforts to Drive Long-term Value Creation Strong Cash Position Supporting Strategic Priorities Upcoming Conference Calls: English Session: March 20 at 8:30 p.m. HKT / 8:30 a.m. ET Chinese Session: March 20 at ...
2026-03-19 19:00
6995
Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China
SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special Administrative Region of China for the treatment of adult patie...
2026-03-19 18:27
4441
Infinitus Showcases Innovations at FHE2026, demonstrating supportive role of complex Polysaccharides on immune health
GUANGZHOU, China, March 18, 2026 /PRNewswire/ -- Infinitus (China) Company Ltd., a company with more than three decades in the traditional Chinese herbal health industry, was invited to participate in the Boao Food for Health Science Conference and Expo (FHE) 2026. During the event held at the Bo...
2026-03-19 09:41
4659
Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study
CHENGDU, China, March 18, 2026 /PRNewswire/ -- The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study (OptiTROP-Lung03) of sacituzumab tirumotecan (sac-TMT, also know...
2026-03-18 22:31
8476
Alphamab Oncology Appoints Mr. Fei Wang as Chief Financial Officer
SUZHOU, China, March 18, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced the appointment of Mr. Fei Wang as Chief Financial Officer (CFO). Mr. Wang will be responsible for the company's capital operations, investment and financing management and investor relations, an...
2026-03-18 21:43
5660
SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support
* Largest-ever grant from RIGHT Foundation to accelerate Phase 1b clinical trial of RSV preventive antibody * Technology licensed from Gates MRI; early studies confirm suppression of RSV infection * Targeting global markets while addressing unmet needs in developing countries INCHEON, South...
2026-03-18 20:00
5367
ProtectHealth strengthen PeKa b40 health screening promotion with Hospital Shah Alam staff in Program Ziarah MADANI
SHAH ALAM, Malaysia, March 18, 2026 /PRNewswire/ -- ProtectHealth Corporation Sdn. Bhd., as an implementing agency under the Ministry of Health Malaysia (MOH), continues to strengthen efforts to promote the Skim Peduli Kesihatan for the B40 group during the Program Ziarah MADANI at Hospital Shah ...
2026-03-18 14:26
4096
Everest Medicines Enters into Letter of Intent with Hasten Biopharmaceuticals (Asia) Limited
SHANGHAI, March 18, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a letter of...
2026-03-18 11:07
9511
Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
SHANGHAI and HONG KONG, March 18, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune ...
2026-03-18 08:30
5536
Breakthrough at 2026 AACR! Senhwa Biosciences' CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy
TAIPEI and SAN DIEGO, March 17, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its first-in-class investigational drug Pidnarule...
2026-03-18 07:00
6698
Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therap...
2026-03-17 20:00
5845
Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models
- In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide. EC50 for human amylin 1 receptor (hAMY1R) was 21.4 pM and 21.2 pM for ASC39 and elo...
2026-03-17 18:00
5698
/C O R R E C T I O N -- Gesynta Pharma/
In the news release, First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat, issued 11-Mar-2026 by Gesynta Pharma over PR Newswire, the source was erroneously mentioned as Getinge Group rather than as Gesynta Pharma as incorrectly transmitted by PR Newswire. The complete, cor...
2026-03-17 17:24
7651
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027
SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) tar...
2026-03-17 10:32
6183
BioCina Initiates Comprehensive Manufacturing Program for Patrys' Proprietary Injectable Therapeutic to Alleviate Delirium
PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd
2026-03-17 09:05
4631
Laronix Launches Voice Restoration Study for ICU Patients at Greater Baltimore Medical Center
NEW YORK, March 16, 2026 /PRNewswire/ -- Laronix, Inc., a commercial-stage medical technology (MedTech) company and industry-leading innovator in voice restoration technologies, and the Greater Baltimore Medical Center (GBMC) announced the launch of an investigational study of Laronix MIRA Voice ...
2026-03-16 22:20
2975
Alar Announced Buprenorphine Injectable, ALA-1000, Demonstrated Long-Term Efficacy and Favorable Safety Profile in Canine Osteoarthritis Pain Management
* A study in client-owned dogs with osteoarthritis demonstrated that a single injection of ALA-1000 effectively mitigates pain and improves functional mobility, with a sustained drug release profile for at least 1 month. The study also confirmed a favorable safety profile with repeated use, par...
2026-03-16 20:00
4039
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
* AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available inthe United States * The launch of AVTOZMA SC further diversifies Celltrion's immunology portfolio beyond TNF-alp...
2026-03-16 20:00
5328
Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call
SHANGHAI, March 16, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial re...
2026-03-16 17:58
6753
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (N...
2026-03-16 10:05
6592
Week's Top Stories
Most Reposted
Tonik Becomes the First Standalone Digital Bank in the Philippines to Achieve Profitability
[Picked up by 297 media titles]
2026-05-12 10:15
Avnet and HKSTP Invite Global Startups to New AI Hardware Launchpad
[Picked up by 292 media titles]
2026-05-12 10:00Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 289 media titles]
2026-05-15 17:00
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 287 media titles]
2026-05-18 15:30
Peach Blossoms Celebrates Three Massive Wins - Black Pearl Restaurant Guide 2026, Asia's 50 Best Restaurants 2026 Extended List and Tatler Best 20 Restaurants in Singapore 2026
[Picked up by 285 media titles]
2026-05-12 14:00
Most Read
Malaysia Healthcare Week Myanmar 2026 Opens in Yangon with Leading Hospitals Showcasing Specialised Care for Myanmar Patients
2026-05-15 22:04
7083
